All In MedTech

Device Trial Radar · NCT07232030

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure (BENEFIT-HF)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,500

Planned (sponsor's estimate)

Start

Apr 24, 2026

Primary completion

Jan 2033

Study completion Jan 2033

Sponsor

Lead sponsor
CVRx, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Nov 18, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF \< 50% and NT-proBNP \< 5,000 pg/mL despite being treated with Guideline-Directed Medical Therapies (medications and devices). It includes demonstration that treatment with the Barostim System, relative to usual care medical management, reduces the rate of all-cause mortality and Heart Failure Morbidity (Cardiac Transplant, Durable LVAD, or Worsening Heart Failure Events).

Conditions

  • Heart Failure
  • Heart Failure NYHA Class II
  • Heart Failure NYHA Class III

Interventions

  • Barostim SystemDevice

    Baroreflex Activation Therapy (BAT) using the Barostim System

  • Usual care medical managementOther

    Usual care medical management alone - no device implant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness EndpointTime frame: Through 24-months follow-up
  2. Primary Safety EndpointTime frame: Within 180 days of the device implant

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Cardiology Associates of Mobile

    Mobile, Alabama · Recruiting

  • PIH Health Good Samaritan Hospital

    Los Angeles, California · Recruiting

  • Keck School of Medicine of USC

    Los Angeles, California · Recruiting

23 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.